Page 1

SENZACELL 29711967 Peter Nählstedt , CEO Positive ESAC opinion on GARD®skin and expanded range of tests open up new commercial opportunities " SenzaGen continues to enjoy strong commercial growth and achieved key successes as a company in the first six months of the year . Our innovative GARD® technology was validated by an independent group of international experts in the summer , making it the first genomic based test to achieve stand - alone status for identifying skin allergens . We broadened our lab operations in line with our strategy by adding more non - animal tests . This creates new opportunities for accelerated sales growth . I would like to thank my predecessor Axel Sjöblad for his excellent work as CEO that made these successes possible , thus creating a stable platform for continuing growth . We will further expand our lab operations in non - animal skin toxicology as soon as this fall , both by launching more tests and by pursuing supplementary mergers and acquisitions , which is a key part of our growth strategy . " Half year 1 January - 30 June >>> Net sales totaled SEK 5,015 ( 3,830 ) thousand . >> The operating loss was SEK -13,995 ( -12,929 ) thousand . » Earnings per share were SEK -0.65 ( -0.60 ) . Cash and cash equivalents at 30 June amounted to SEK 75,571 ( 101,536 ) thousand . SenzaGen AB • January - June 2021 Interim Report SENZA GEN Half - yearly report >>> JANUARY - JUNE 2021 Significant events during the first half year >>> Lab operations were broadened within in vitro skin toxicology . >> SenzaGen received an SEK 0.6 million GARDⓇ order from a new European customer in the chemicals industry . Collaboration with RIFM on the safe use of fragrances with GARD®skin Dose - Response was expanded with an SEK 1.2 million grant . >>> The global collaboration agreement with Charles River Laboratories was renewed and expanded . ● 1/13 Significant events after the end of the period >> Peter Nählstedt was appointed CEO . >>> A very positive opinion on GARD®skin from ESAC experts paves the way for OECD validation . >>> An SEK 0.65 million order for GARD®skin Dose - Response was secured from one of the world's largest cosmetics companies . An SEK 0.65 million order for skin allergy and irritation tests was received from a global consumer products company .